Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-03-31

FDA Approved: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE — Supplemental Application (H2-Pharma, LLC)

View source ↗

Summary

The FDA approved a supplemental application for the fixed-dose combination of bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride by H2-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bismuth Subcitrate Potassium (bismuth subcitrate potassium)
  • METRONIDAZOLE (Metronidazole)
  • Tetracycline Hydrochloride (tetracycline hydrochloride)

Snippet

SUPPL AP for BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE)